



GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurgaon (Haryana), India-122002

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

November 7, 2017

The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

The Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C – 1, Block – G
Bandra-Kurla Complex, Bandra
Mumbai – 400 051

Dear Sir/Madam,

Sub: Unaudited Financial Results for the quarter ended on 30 September 2017

We would like to inform you that the Board of Directors at its meeting held on Tuesday, November 7, 2017 at 2:00 p.m. at its Corporate office at 24 & 25 Floor, One Horizon Centre, DLF Phase V, Golf Course Road, Gurgaon 122 002, have, inter alia, considered and taken on record the unaudited financial results for the quarter ended September 30, 2017. We are enclosing a copy of the Unaudited Financial Results for the quarter ended September 30, 2017 along with the "Limited Review" Certificate, issued by the Statutory Auditors for the review done by them, for your records.

The above may please be taken as our intimation under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You

Yours faithfully
For GlaxoSmithKline
Consumer Healthcare Limited

Shanu Saksena
Company Secretary
M. No. ACS-13405

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).
Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram- 122 002, Haryana.
Tel. No. 01765-306400; Fax No. 01765-220642

CIN: L24231PB1958PLC002257
Email ID: investor.2.co@gsk.com
Website: www.gsk-ch.in



Statement of Unaudited Financial Results for the quarter and half year ended September 30, 2017							(Rs. in Lakhs)
Particulars	For the quarter ended			For the half year ended		For the year ended	
	30/09/2017	30/06/2017	30/09/2016	30/09/2017	30/09/2016	31/03/2017	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Income							
(a) Revenue from operations	11,15,32	10,45,88	11,92,76	21,61,20	22,52,14	44,21,09	
(b) Other income	54,97	55,69	57,82	1,10,66	1,17,00	2,43,88	
Total Income	11,70,29	11,01,57	12,50,58	22,71,86	23,69,14	46,64,97	
2 Expenses							
(a) Cost of materials consumed	3,05,59	3,16,76	3,04,44	6,22,35	5,93,41	11,50,75	
(b) Purchase of stock-in-trade	42,26	29,89	40,58	72,15	65,53	1,53,85	
(c) Changes in inventories of work-in-progress, stock-in-trade and finished goods	46,09	(4,04)	22,13	42,05	(15,54)	(7,66)	
(d) Excise duty (Refer Note 3)	-	60,54	1,12,49	60,54	2,27,97	4,34,63	
(e) Employee benefits expense	1,29,71	1,33,75	1,30,74	2,63,46	2,47,75	4,58,03	
(g) Depreciation and amortisation expense	17,68	17,01	14,75	34,69	29,42	64,18	
(h) Other expenses							
(i) Advertising and promotion	1,37,10	1,27,84	1,27,19	2,64,94	2,48,74	5,14,67	
(ii) Others	1,93,21	2,14,79	2,10,02	4,08,00	4,35,59	8,83,33	
(l) Finance costs	55	54	64	1,09	1,28	2,78	
Total Expenses	8,72,19	8,97,08	9,62,98	17,69,27	18,34,15	36,54,56	
3 Profit before tax (1-2)	2,98,10	2,04,49	2,87,60	5,02,59	5,34,99	10,10,41	
4 Income tax expense							
(a) Current tax	1,02,60	69,87	1,08,68	1,72,48	1,97,79	3,70,24	
(b) Deferred tax	3,09	2,39	(4,80)	5,48	(7,13)	(16,50)	
Total tax expense	1,05,69	72,26	1,03,88	1,77,96	1,90,66	3,53,74	
5 Profit for the period (3-4)	1,92,41	1,32,23	1,83,72	3,24,63	3,44,33	6,56,67	
6 Other comprehensive income							
(i) Items that will not be reclassified to profit or loss							
Remeasurements of post-employment benefit obligations	9,88	-	12,83	9,88	10,66	33,04	
(ii) Income tax relating to items that will not be reclassified to profit or loss	(3,42)	-	(4,44)	(3,42)	(3,69)	(11,44)	
Total other comprehensive income, net of income tax	6,46	-	8,39	6,46	6,97	21,60	
7 Total comprehensive income for the period (5+6)	1,98,87	1,32,23	1,92,11	3,31,09	3,51,30	6,78,27	
8 Paid up equity share capital	42,06	42,06	42,06	42,06	42,06	42,06	
(Face value of Equity Shares)	10	10	10	10	10	10	
9 Earnings per share (of Rs 10/- each) (not annualised):							
(a) Basic	45.75	31.44	43.68	77.18	81.87	156.15	
(b) Diluted	45.75	31.44	43.68	77.18	81.87	156.15	



Particulars	As at (30/09/2017) (Unaudited)	As at (31/03/2017) (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	4,77,09	4,87,04
Capital work-in-progress	43,80	49,18
Intangible assets	23	39
Intangible assets under development	8,84	8,49
Financial assets		
i. Loans	23,86	30,57
ii. Other financial assets	22,83	21,71
Deferred tax assets (net)	1,18,91	1,27,80
Tax assets (net)	63,64	81,70
Other non-current assets	7,42	8,67
Total non-current assets	7,66,62	8,15,55
Current assets		
Inventories	3,90,08	4,61,14
Financial assets		
i. Trade receivables	3,76,02	3,21,00
ii. Cash and cash equivalents	5,90,94	7,00,91
iii. Bank balances other than (ii) above	25,83,90	23,86,46
iv. Loans	13,11	11,68
v. Other financial assets	1,66,14	1,54,24
Employee Benefits	11,16	7,29
Other current assets	2,12,79	1,01,90
Total current assets	43,44,14	41,44,62
Total assets	51,10,76	49,60,17
EQUITY AND LIABILITIES		
Equity		
Equity share capital	42,06	42,06
Other equity	30,57,40	30,80,61
Total equity	30,99,46	31,22,67
LIABILITIES		
Non-current liabilities		
Provisions	2,21,37	1,71,62
Employee benefit obligations	88,84	64,77
Total non-current liabilities	3,10,21	2,36,39
Current liabilities		
Financial Liabilities		
(i) Trade payables	8,49,63	8,60,41
(ii) Other financial liabilities	3,61,94	3,32,33
Provisions	1,72,93	2,64,16
Employee benefit obligations	17,35	40,63
Other current liabilities	2,99,24	1,03,58
Total current liabilities	17,01,09	16,01,11
Total liabilities	20,11,30	18,37,50
Total equity and liabilities	51,10,76	49,60,17



Notes:

1. The above results were reviewed by the Audit committee and approved by the Board of Directors in their meeting held on November 7, 2017. Results for the quarter and half year ended September 30, 2017 have been subjected to limited review by the statutory auditors. The results for the quarter and half year ended September 30, 2016 and year ended March 31, 2017 were subjected to limited review by the previous statutory auditors.
2. The above results have been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. Consequent to introduction of Goods and Services (GST) with effect from 1st July, 2017. Central Excise, Value Added Tax (VAT) etc. have been subsumed into GST. In accordance with Indian Accounting Standard – 18 on Revenue and Schedule III of the Companies Act, 2013, unlike Excise Duties, levies like GST, VAT, etc. are not part of Revenue. Accordingly, the figures for the periods upto 30th June 2017 are not strictly relatable to those thereafter.
4. Based on the guiding principles given in Ind AS 108 on 'Operating segments', the Company's business activity falls within a single operating segment, namely Nutrition. Accordingly, the disclosure requirements of Ind AS 108 are not applicable.

Place: Gurugram
Date : November 7, 2017



ON BEHALF OF THE BOARD OF DIRECTORS

Manoj Kumar

Manoj Kumar
Managing Director
DIN: 07177262



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
GlaxoSmithKline Consumer Healthcare Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **GlaxoSmithKline Consumer Healthcare Limited** ("the Company"), for the quarter and half year ended September 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Manjula Banerji
Partner

(Membership No. 086423)


Gurugram, November 07, 2017